前列腺放疗患者急性与晚期毒性的相互作用:六项随机试验的个体患者数据Meta分析
该个体患者数据Meta分析纳入六项随机3期试验中6593例接受常规或中度大分割前列腺放疗的患者,评估急性(放疗后≤3个月)与晚期(>3个月)≥2级泌尿生殖及胃肠道毒性的关联。急性≥2级泌尿生殖毒性关联晚期≥2级泌尿生殖毒性(OR 2.20,95%CI 1.88-2.57,p<0.0001)及尿生活质量下降≥2倍MCID(1.41,1.17-1.68,p=0.0002);急性≥2级胃肠道毒性关联晚期≥2级胃肠道毒性(2.53,2.07-3.08,p<0.0001)及肠道生活质量下降≥2倍MCID(1.52,1.26-1.83,p<0.0001)。
要点
- 急性≥2级泌尿生殖毒性关联晚期≥2级泌尿生殖毒性,OR 2.20(95%CI 1.88-2.57)。
- 急性≥2级胃肠道毒性关联晚期≥2级胃肠道毒性,OR 2.53(95%CI 2.07-3.08)。
- 急性毒性还与患者报告生活质量下降≥2倍MCID相关。
核心结论
- 前列腺放疗后急性毒性与晚期毒性及患者报告生活质量指标下降呈统计学显著关联。
- 这些数据支持评估减少急性毒性的干预措施是否最终降低晚期毒性风险。
研究设计与样本
- 个体患者数据Meta分析,纳入MARCAP联盟中六项常规或中度大分割前列腺放疗随机3期试验。
- 共纳入6593例患者(常规分割n=4248;中度大分割n=2345),中位随访72个月(IQR 61-94)。
- 急性毒性定义为放疗后≤3个月,晚期毒性定义为放疗后>3个月。
- 采用校正广义线性混合模型,校正年龄、雄激素剥夺治疗状态、放疗类型、放疗剂量和放疗方案。
主要发现
- 急性≥2级泌尿生殖毒性关联晚期≥2级泌尿生殖毒性(OR 2.20,95%CI 1.88-2.57,p<0.0001)。
- 急性≥2级泌尿生殖毒性关联尿生活质量下降≥2倍MCID(OR 1.41,95%CI 1.17-1.68,p=0.0002)。
- 急性≥2级胃肠道毒性关联晚期≥2级胃肠道毒性(OR 2.53,95%CI 2.07-3.08,p<0.0001)。
- 急性≥2级胃肠道毒性关联肠道生活质量下降≥2倍MCID(OR 1.52,95%CI 1.26-1.83,p<0.0001)。
关键数值与推荐
- 急性≥2级泌尿生殖毒性与晚期≥2级泌尿生殖毒性的OR为2.20(95%CI 1.88-2.57,p<0.0001)。
- 急性≥2级胃肠道毒性与晚期≥2级胃肠道毒性的OR为2.53(95%CI 2.07-3.08,p<0.0001)。
- 急性≥2级泌尿生殖毒性与尿生活质量下降≥2倍MCID的OR为1.41(95%CI 1.17-1.68,p=0.0002)。
- 急性≥2级胃肠道毒性与肠道生活质量下降≥2倍MCID的OR为1.52(95%CI 1.26-1.83,p<0.0001)。
临床怎么用
- 原文结论指出这些数据支持评估减少急性毒性的干预措施是否最终降低晚期毒性风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The association between acute and late toxicity following prostate radiotherapy has not been well studied using data from multiple randomised clinical trials and fractionation schedules. We aimed to characterise the relationship between acute and late genitourinary and gastrointestinal toxicity among patients receiving conventionally fractionated or moderately hypofractionated prostate radiotherapy. METHODS: This was an individual patient data meta-analysis that identified randomised phase 3 trials of conventionally fractionated or moderately hypofractionated prostate radiotherapy in the Meta-Analysis of Randomized trials in Cancer of the Prostate (MARCAP) Consortium that had individual-level acute and late toxicity data available and were available before Dec 1, 2023. Trials without individual patient data were excluded. Data were provided to MARCAP by study investigators. The associations between acute (≤3 months after radiotherapy) and late (>3 months after radiotherapy) grade 2 or greater genitourinary and gastrointestinal toxicities were assessed using adjusted generalised linear mixed models (adjusted for age, androgen deprivation therapy status, type of radiotherapy, radiation dose, and radiation schedule). In the subset of trials that collected Expanded Prostate Cancer Index Composite quality of life (QOL) evaluations, the association between acute genitourinary and gastrointestinal toxicity and decrements at least twice the minimal clinically important difference (MCID) for urinary and bowel QOL were also evaluated. FINDINGS: Six of 26 available trials met all the eligibility criteria. 6593 patients were included (conventionally fractionated: n=4248; moderately hypofractionated: n=2345). Median follow-up was 72 months (IQR 61-94). Acute grade 2 or greater genitourinary toxicity was associated with both late grade 2 or greater genitourinary toxicity (odds ratio 2·20 [95% CI 1·88-2·57], p<0·0001) and decrement at least twice the MCID in urinary QOL (1·41 [1·17-1·68], p=0·0002). Acute grade 2 or greater gastrointestinal toxicity was associated with both late grade 2 or greater gastrointestinal toxicity (2·53 [2·07-3·08], p<0·0001) and decrement at least twice the MCID in bowel QOL (1·52 [1·26-1·83], p<0·0001). INTERPRETATION: Acute toxicity following prostate radiotherapy was statistically significantly associated with late toxicity and with decrement in patient-reported QOL metrics. These data support efforts to evaluate whether interventions that reduce acute toxicity ultimately reduce the risk of late toxicity. FUNDING: National Institutes of Health and US Department of Defense.
引用
- Nikitas J, Jamshidian P, Tree AC, et al. The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials. Lancet Oncol. 2025. PMID: 39894025. doi:10.1016/S1470-2045(24)00720-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。